T cell receptor Vbeta repertoire expression reflects gastric carcinoma progression.

Institute of Digestive Diseases, Fourth Military Medical University, Xian, People's Republic of China.
Clinical Immunology (Impact Factor: 3.99). 11/2001; 101(1):3-7. DOI: 10.1006/clim.2001.5100
Source: PubMed

ABSTRACT Analysis of TCR beta-chain complementarity-determining region size gives an indication of the T cell immune response. We examined CD4+ and CD8+ subgroups of T cells in the peripheral blood (PBL), benign gastric mucosa, and tumor (TIL) lymphocytes of 12 patients with primary gastric carcinomas of both intestinal and diffuse types. The average number of expanded clones in each compartment, expressed by the 24 families of the TCRVbeta repertoire, was analyzed according to tumor histological type, maximal invasive depth, and lymph node metastases. Fewer clones were expressed by the PBL in the cases with lymph node metastases than in those without (CD4+ P = 0.00017, CD8+ P = 0.016). Fewer CD8+ clones were expressed by the PBL in the cases with full thickness tumor infiltration than in those involving only the mucosa and submucosa (P = 0.05). The CD8+ TIL showed significantly fewer clones in the diffuse-type carcinoma than in the intestinal type (P = 0.046).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To study T cell immunology in patients with colorectal cancer, the molecular features of clonal expanded T cell in TIL and PBL were analyzed by assessment of TCRβ gene reopertoire. Methods: The rearranged V-J genes of TCRβ chain were amplified by RT-PCR and separated with denaturation polyacrylamide sequencing gel eletrophoresis. The PCR products were sequenced directly to determine the characteristics of the clonal expanded transcripts. Results: There were oligoclonal expanded transcripts of TCRβ V genes both in TIL and PBL from pre-operation patients, which all disappeared in PBL after operation. The amino acid sequences of the CDR3 regions in these oligoclonal expanded T cells suggested that they related with the tumor peptide-specific activation. Existence of clonal expanded T cells in PBL may have relevance with the recurrence. Conclusion: Tumor peptide-specific Activated T cell clones were found not only in TIL of colorectal cancer tissue, but also in PBL of tumor-bearing patients. The activation of systemic T cell immunology may play an important role in the prognosis of patients.
    Chinese Journal of Cancer Research 12/2003; 15(4):277-281. DOI:10.1007/BF02974892 · 0.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastric cancer (GC) is still one of the leading causes of cancer death. The mechanism of tumor genesis and progression is very complicated, which may include several immune and molecular factors. Genesis of GC is still unclear, while H pylori associated inflammation is regarded as one of the causes, in which multiple molecule such as CagA and VacA may play important roles. While GC is progressing, tumor cells always induce cell apoptosis or dysfunction in immune system to obtain immune privilege or immune evasion. During this process, CD4+ T cells, CD8+ T cells and dendritic cells are involved. Besides, many kinds of growth factors, cytokines and adhesion molecules may induce and enhance this process. Immunotherapy as a adjuvant treatment for GC has already been studied intensively and promising results have been achieved.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. To explore the expression of the TRAV gene in peripheral blood mononuclear cells (PBMCs) and in tumor-infiltrating lymphocytes (TILs) in the patients with breast cancer using a DNA melting curve (FQ-PCR) technique for T cell receptor (TCR) alpha chain CDR3 spectratyping. Peripheral blood samples and tissue samples were obtained from thirty breast cancer patients. Total RNA was extracted from PBMCs and tumor tissues and then reverse transcribed into cDNA. FQ-PCR was used to amplify the human TCR alpha chain CDR3 region with the primers to the TRAV and TRAC genes. TCR alpha chain CDR3 spectratyping and partial CDR3 sequencing were used to determine use of TRAV gene product in T cell responses. TCR alpha CDR3 spectratyping showed preferential usage of certain TRAV genes in the PBMCs and TILs of all patients with breast cancer. The frequencies of TRAV1.1, TRAV9, and TRAV29 exceeded 30% in PBMCs and the frequencies of TRAV1.1 and TRAV22 exceeded 30% in TILs. More than three quarters of the patients (23/30) overexpressed the same gene in both PBMCs and TILs; for example, patient-1 highly expressed TRAV9 in the PBMCs and TILs. Patients with positive or negative tumor markers of estrogen receptor (ER), progesterone receptor (PR), pS2, C-erbB-2, nm23, P53, and Ki-67 showed no significant common TRAIT gene expression, but some TRAV gene preferential usage frequencies exceeded 20%. For example, five of eight patients positive for ER had high levels of expression of TRAV1.1 and TRAV32. Finally, the amino acid sequence of TCR CDR3 region showed some common motifs in some of the patients. Conclusions. TRAIT gene expression was complex and diverse in the patients with breast cancer. The TRAIT gene usage may be closely related to the diversity of breast tumor antigens and the differential immune responses observed in individual patients. Research into the immunological mechanism of T cells may provide guidance for individual T cell-directed therapy for breast cancer.
    Neoplasma 08/2012; 59(6):693-9. DOI:10.4149/neo_2012_088 · 1.64 Impact Factor